drugset / Trial / NCT07024173

A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer

NCT07024173

Phase 3 Recruiting 240 enrolled Shandong Suncadia Medicine Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is a multicenter, open-label, randomized controlled Phase 3 clinical trial. It is planned to enroll 240 female patients with locally advanced or metastatic breast cancer followed by disease progression after previous endocrine therapy.

Timeline

Start
2025-07-23
Primary completion
2026-12
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Anastrozole Other / unclassified Oral
Comparator Everolimus Small molecule Oral
Comparator Exemestane Small molecule Oral
Comparator Fulvestrant Small molecule Other
Subject HRS-8080 Unknown Oral
Comparator Letrozole Other / unclassified Oral